Education
About Us
Working with TipRanks
Follow Us
NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
NMTC Stock Chart & Stats
$0.71
-$0.09(-8.05%)
At close: 4:00 PM EST
$0.71
-$0.09(-8.05%)
Day’s Range― - ―
52-Week Range$0.40 - $1.39
Previous CloseN/A
Volume212.44K
Average Volume (3M)532.45K
Market Cap
$45.32M
Enterprise Value$29.25M
Total Cash (Recent Filing)$6.57M
Total Debt (Recent Filing)$266.81K
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Feb 17, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding50,413,147
10 Day Avg. Volume702,340
30 Day Avg. Volume532,447
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)3.92
P/FCF Ratio-12.22
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue3.22
Enterprise Value/Gross Profit5.69
Enterprise Value/Ebitda-9.72
Forecast
1Y Price Target
$3.00Price Target Upside322.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Technology DifferentiationFDA-cleared, minimally invasive high-definition electrode platform offers reduced brain trauma and enables combined diagnostic and therapeutic procedures, potentially increasing clinical preference over standard electrodes.
Commercial Adoption And PartnershipsGrowing physician adoption supported by expansion of trained sales representatives through the Zimmer Biomet partnership can accelerate procedure volume and revenue build-out.
Pipeline And Market ExpansionAdvancement beyond epilepsy—including successful trigeminal neuralgia treatments and positive in‑animal spinal cord stimulation results that enable first-in-human trials—extends access into a broader chronic pain market.
Bears Say
Financing And Dilution RiskWidening projected losses increase the likelihood of additional financing needs, which could dilute existing shareholders or occur on unfavorable terms.
Investor Sentiment And Valuation RiskExpanding losses may undermine investor confidence and limit valuation re-rating potential relative to peers, capping upside for the stock.
Rising Operating ExpensesHigher expected operating expenses are widening GAAP loss per share estimates for fiscal 2026 and 2027, pressuring profitability.
NeuroOne Medical Technologies News
NMTC FAQ
What was NeuroOne Medical Technologies’s price range in the past 12 months?
NeuroOne Medical Technologies lowest stock price was $0.40 and its highest was $1.39 in the past 12 months.
What is NeuroOne Medical Technologies’s market cap?
NeuroOne Medical Technologies’s market cap is $45.32M.
When is NeuroOne Medical Technologies’s upcoming earnings report date?
NeuroOne Medical Technologies’s upcoming earnings report date is Feb 17, 2026 which is in 30 days.
How were NeuroOne Medical Technologies’s earnings last quarter?
NeuroOne Medical Technologies released its earnings results on Dec 17, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.04 by -$0.01.
Is NeuroOne Medical Technologies overvalued?
According to Wall Street analysts NeuroOne Medical Technologies’s price is currently Undervalued.
Does NeuroOne Medical Technologies pay dividends?
NeuroOne Medical Technologies does not currently pay dividends.
What is NeuroOne Medical Technologies’s EPS estimate?
NeuroOne Medical Technologies’s EPS estimate is -0.04.
How many shares outstanding does NeuroOne Medical Technologies have?
NeuroOne Medical Technologies has 50,413,147 shares outstanding.
What happened to NeuroOne Medical Technologies’s price movement after its last earnings report?
NeuroOne Medical Technologies reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.04. Following the earnings report the stock price went down -5.382%.
Which hedge fund is a major shareholder of NeuroOne Medical Technologies?
Currently, no hedge funds are holding shares in NMTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroOne Medical Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (322.54% Upside)
$3.00 (322.54% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.0%
Last 30 Days ▲ 22.5%
Last 30 Days ▲ 22.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.29%
12-Months-Change
Fundamentals
Return on Equity
-91.34%
Trailing 12-Months
Asset Growth
120.24%
Trailing 12-Months
Company Description
NeuroOne Medical Technologies
NeuroOne Medical Technologies (NMTC) is a medical device company focused on developing innovative solutions for neurological disorders, specifically targeting conditions such as epilepsy and chronic pain. The company operates within the healthcare sector, primarily specializing in advanced electrode technology and implantable devices designed for brain monitoring and stimulation. NMTC's core products include its ultra-thin and flexible electrode arrays, which are intended to improve the treatment outcomes for patients undergoing neurological procedures.
NMTC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record product sales growth, improved gross margins, and successful FDA clearances. However, the company faces ongoing challenges with NASDAQ compliance and managing net losses. Overall, the positive aspects of growth and strategic developments outweigh the challenges.View all NMTC earnings summariesNMTC Stock 12 Month Forecast
Average Price Target
$3.00
▲(322.54% Upside)
Technical Analysis
Sensus Healthcare
―
Electrocore
―
Modular Medical
―
Vicarious Surgical
―
Inspira Technologies Oxy BHN
―
Ownership Overview
11.39% Insiders
3.22% Mutual Funds
0.17% Other Institutional Investors
82.67% Public Companies and
Individual Investors